These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34006672)

  • 1. [Therapeutic Apheresis in Neurological Disorders].
    Nakatsuji Y
    Brain Nerve; 2021 May; 73(5):425-430. PubMed ID: 34006672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoadsorption in neurological disorders.
    Oji S; Nomura K
    Transfus Apher Sci; 2017 Oct; 56(5):671-676. PubMed ID: 28919008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic indications for therapeutic plasma exchange: an update.
    Gwathmey K; Balogun RA; Burns T
    J Clin Apher; 2011; 26(5):261-8. PubMed ID: 21915895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of therapeutic plasma exchange for pediatric neurological diseases.
    Ipe TS; Meyer EK; Sanford KW; Joshi SK; Wong ECC; Raval JS
    J Clin Apher; 2021 Feb; 36(1):161-176. PubMed ID: 33063869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic indications for therapeutic plasma exchange: 2011 update.
    Gwathmey K; Balogun RA; Burns T
    J Clin Apher; 2012; 27(3):138-45. PubMed ID: 22522566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of therapeutic apheresis in neurological diseases and comparison between plasma exchange and immunoadsorption].
    Loschiavo C; Grecò M; Polo A; Del Colle R
    G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The top clinical trial opportunities in therapeutic apheresis and neurology.
    Morgan SM; Shaz BH; Pavenski K; Meyer EK; Delaney M; Szczepiorkowski ZM
    J Clin Apher; 2014 Dec; 29(6):331-5. PubMed ID: 24899381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic apheresis in neurology critical care.
    Natarajan N; Weinstein R
    J Intensive Care Med; 2005; 20(4):212-25. PubMed ID: 16061904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination].
    Topuzova MP; Bisaga GN; Alekseeva TM; Isabekova PS; Сhaykovskaya AD; Panina EB; Pavlova TA; Ternovykh IK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):97-106. PubMed ID: 32844638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange in neurological disease.
    Osman C; Jennings R; El-Ghariani K; Pinto A
    Pract Neurol; 2020 Apr; 20(2):92-99. PubMed ID: 31300488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.
    Mori S; Kurimoto T; Ueda K; Nakamura M
    Jpn J Ophthalmol; 2018 Jul; 62(4):525-530. PubMed ID: 29802557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis optica spectrum disorder presenting with concurrent autoimmune diseases.
    Bibic VC; Brust TB; Burton JM
    Mult Scler Relat Disord; 2019 Feb; 28():125-128. PubMed ID: 30593981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world application of plasmapheresis for neurological disease: Results from the Japan-Plasmapheresis Outcome and Practice Patterns Study.
    Lin Y; Oji S; Miyamoto K; Narita T; Kameyama M; Matsuo H
    Ther Apher Dial; 2023 Feb; 27(1):123-135. PubMed ID: 35765859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in the frequency of use of apheresis and biological drugs in the treatment of neuromyelitis optica spectrum disorders.
    Miyamoto K; Nakayama Y; Ito H
    Ther Apher Dial; 2023 Aug; 27(4):819-820. PubMed ID: 36826431
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic apheresis in neurological disorders.
    Weinstein R
    J Clin Apher; 2000; 15(1-2):74-128. PubMed ID: 10767052
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review.
    Jacob S; Mazibrada G; Irani SR; Jacob A; Yudina A
    J Neuroimmune Pharmacol; 2021 Dec; 16(4):806-817. PubMed ID: 34599742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Optic Neuritis: A Neuromyelitis Optica Spectrum Disorder.
    Alam M; Haq MAU; Iqbal A; Ullah K; Nabi D
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):379-380. PubMed ID: 30925966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis.
    Bates M; Chisholm J; Miller E; Avasarala J; Guduru Z
    Mult Scler Relat Disord; 2020 Sep; 44():102205. PubMed ID: 32526697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.